Here is a situation that plays out constantly and that almost no family sees coming.
Your loved one goes into detox. At some point during that stay, the medical team starts them on a medication called buprenorphine, usually under the brand name Suboxone. It works. The withdrawal becomes manageable, the cravings quiet down, and for the first time in a long while they seem like themselves.
Then comes the next decision, and nobody explains that it's a decision at all. Do they taper off the medication before moving to residential treatment, or do you find a program that will let them stay on it?
That choice has real consequences, and the answer you get depends heavily on which facility you happen to be talking to. Here's what families should understand before that conversation happens.
What MAT Actually Is
Medication-assisted treatment, usually shortened to MAT, refers to FDA-approved medications used to treat substance use disorders. You'll also see the term MOUD, which stands for medications for opioid use disorder and is the more precise term.
For opioid addiction there are three:
Buprenorphine. Sold as Suboxone, Subutex, and in long-acting injectable form as Sublocade or Brixadi. It reduces cravings and prevents withdrawal.
Methadone. The oldest of the three, dispensed daily through licensed opioid treatment programs rather than a regular pharmacy.
Naltrexone. Sold as Vivitrol in its monthly injectable form. It works differently, blocking opioid effects rather than reducing withdrawal, and it requires someone to be fully detoxed before starting.
Buprenorphine and methadone act on the same receptors opioids do, which is where a lot of the argument in this field comes from. Some people describe that as trading one drug for another. Clinically it isn't. At a stable dose there's no high. What there is instead is a person who can hold a job, show up for their kids, and actually participate in therapy rather than organizing their entire day around not being sick.
The major clinical bodies settled this question years ago. These medications are the standard of care for opioid use disorder, and buprenorphine and methadone are the two treatments with the strongest evidence for reducing overdose death. The disagreement that remains is philosophical, and it lives inside individual treatment programs.
Starting the Medication Is Harder Than It Used to Be
This part matters because it shapes what happens in detox, and because it's changing fast enough that not every facility has kept up.
The traditional way to start someone on buprenorphine was to wait until they were already in withdrawal, usually 12 to 24 hours after their last opioid use, then give a standard dose. That protocol was built when heroin and prescription pills dominated the supply, and it worked reasonably well.
Fentanyl broke it. Fentanyl is highly lipophilic, meaning it accumulates in the body's fatty tissue and releases slowly over time, so someone can still have meaningful amounts in their system days after their last use. If buprenorphine is introduced while that's still happening, it can displace the fentanyl from the receptors and trigger what's called precipitated withdrawal, which is a sudden, severe withdrawal that's worse than what the person came in with.
It's worth saying clearly that this doesn't happen to everyone. A prospective emergency department trial found a rate under 1%, which is far lower than the case reports suggest. But that study took place in an emergency room, where patients could be monitored continuously and full agonist opioids were available if something went wrong, and the researchers themselves noted this makes the findings difficult to apply to other settings. A detox unit inside a residential facility is not an emergency room. What happens during induction depends heavily on where it happens and what that place is equipped to do.
The alternative approach is called low-dose initiation, sometimes referred to as microdosing or the Bernese method. Instead of waiting for withdrawal, the patient starts on very small doses of buprenorphine and increases gradually over several days, which avoids the displacement problem entirely.
Why this matters for your family: a detox facility still running the old protocol on someone coming off fentanyl may put your loved one through a brutal experience that convinces them the medication doesn't work for them. It's worth asking directly what approach a facility uses.
The Taper Decision
Once someone is stabilized, the question becomes whether they stay on the medication.
Here's the honest version. There is no clinical rule that says someone should come off buprenorphine at a particular point. The evidence consistently shows that longer time on medication is associated with better outcomes, and that people who discontinue face elevated overdose risk, particularly in the period right after stopping when tolerance has dropped.
That doesn't mean everyone stays on it forever. Some people taper successfully once they have stable housing, work, and support in place. But the decision should be driven by that person's clinical situation and their prescriber's judgment, not by a facility's admission policy.
That distinction is the whole ballgame, and it's where families get caught.
Many Programs Won't Take Someone Who's On It
This is more common than most families expect, and it usually doesn't come up until you ask directly.
A 2024 study surveyed 100 certified recovery residences in South Florida, with researchers calling each one posing as someone seeking placement. Only 16% accepted people on any dose of buprenorphine. Another 31% had conditional policies, and 53% prohibited it outright.
The conditions on that middle group are the part worth knowing. Of the residences with conditional policies, about a quarter required a mandatory taper, and roughly 39% capped the dose at 8mg daily regardless of what the person's prescriber had determined was appropriate.
That dose cap is where families get blindsided. A program can honestly say it accepts people on Suboxone while requiring a reduction from a stable dose to one nobody clinically chose. The answer wasn't dishonest. The question just wasn't specific enough.
The pattern holds in programs serving young people too. A study that called 354 residential adolescent treatment centers found only about 1 in 4 offered buprenorphine, and 22% required that a young person not be taking it at all in order to be admitted.
Why This Happens
Part of it comes down to a disagreement about what the word sober means.
In much of the traditional treatment world, sobriety has meant the absence of all mood-altering substances, and some programs include prescribed buprenorphine and methadone in that definition. Under that framing, a person stable on medication isn't considered to be in recovery at all.
That framing predates the current evidence base, and it persists in some programs and some peer communities. It explains why two facilities that look nearly identical from the outside can give you completely opposite answers to the same question, and why the answer often has more to do with the program's philosophy than with your loved one's clinical picture.
It's also worth knowing that for licensed housing, blanket bans on prescribed medication may run into problems under the Americans with Disabilities Act and the Fair Housing Act. That's a live legal question rather than a settled one, but it's a reason not to accept the policy as simply how things are done.
Sublocade and the Injectable Option
If your loved one is going to be on buprenorphine, the monthly injectable version is worth asking about specifically. Sublocade is the main one, and Brixadi is a newer alternative with weekly and monthly formulations.
What it solves:
No daily dosing. The medication is administered once a month by a provider, so there's no bottle to lose, no daily decision to make, and no film to divert or sell.
Steady blood levels. Rather than a peak and decline each day, the level stays consistent, which some people find makes cravings easier to manage.
It closes the discharge gap. This is the big one, and I'll come back to it. Someone who receives an injection before leaving treatment is covered for a month regardless of how long it takes to get in with a new prescriber.
What families should also know: it requires stabilization on the oral form first, so it isn't a day-one option. It's expensive and insurance coverage varies considerably. And once it's administered, the dose can't be adjusted downward until it wears off, which matters if someone has side effects.
It's not right for everyone. But it solves a specific problem that causes real harm, and plenty of facilities don't bring it up on their own.
The Question Almost Nobody Asks
Admission policy is the part families learn to ask about. Discharge is where the actual damage happens.
Picture the sequence. Someone finishes a residential stay, stable on buprenorphine, and is discharged. If nobody arranged for a prescriber to continue the medication, there's now a gap between the day the prescription runs out and the day they can get an appointment. That gap can be days or weeks.
Two things can happen in that window. They go into withdrawal, which is the exact state the medication exists to prevent. Or they use, with a tolerance that dropped during treatment, which is the single highest-risk period for fatal overdose in the entire treatment process.
This isn't a rare failure. A 2025 study of 107 outpatient buprenorphine programs in Philadelphia found that only 42% could confirm whether a prescription was even possible at a first visit, and 48% couldn't provide information about their own counseling requirements. If programs can't answer basic questions about their own policies over the phone, then a discharge plan that consists of a list of numbers to call is not a plan.
What to Ask Before Admission
- Do you admit and keep people on buprenorphine or methadone
- Is there a maximum dose you'll allow, and what is it
- Would you require a taper during the stay, and who makes that decision, your clinical team or program policy
- If my loved one's prescriber disagrees with a taper, how is that handled
- What induction approach do you use for someone coming off fentanyl
- Do you offer Sublocade or Brixadi, and would my loved one be a candidate
- Do your groups and staff treat someone on medication as being in recovery
That last one isn't a paperwork question. If the program's culture treats medication as a lesser form of sobriety, your loved one will feel it in group every single day, and that affects whether they stay.
What to Ask About Discharge, Before Admission
Ask these on the way in, not on the way out. By the time discharge planning starts, the options have already narrowed.
- Do you write a bridge prescription at discharge, and how many days does it cover
- Will the follow-up appointment be scheduled before my loved one leaves, or will they be handed a list of numbers
- Who is the prescriber, and have you confirmed they take our insurance and are accepting new patients
- What happens if the first available appointment is further out than the bridge prescription covers
- Would an injection before discharge be an option
- Who at your facility is responsible for making sure this connection actually happens
A program that has thought about this will name a person and describe a process. A program that hasn't will talk about discharge planning in general terms and move on.
A Note on Alcohol
Medication for alcohol use disorder exists too, and it comes up far less often than it should. Naltrexone reduces cravings and blunts the reinforcing effect of drinking. Acamprosate helps with stabilization after someone stops. Disulfiram, sold as Antabuse, causes an unpleasant physical reaction if someone drinks while taking it.
These are underused, and many families are never told they're an option. The dynamics are different enough from opioid medication that they deserve their own discussion, but the core question is the same: does this facility offer medication as part of treatment, or does it treat medication as something to get off of?
You Don't Have to Sort This Out Alone
Knowing what to ask is the first half. Knowing whether an answer is any good is the second half, and that's harder when you're making decisions quickly and under real pressure.
If you're trying to figure out whether a program will actually support your loved one's medication, or you want help making sure there's no gap between discharge and the next prescriber, that's the kind of situation I work through with families. Book a consultation here.